Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
249.18
-7.34 (-2.86%)
Aug 11, 2026, 11:04 AM EDT - Market open
Jazz Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 4,601 | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 |
Revenue Growth | 12.59% | 4.88% | 6.12% | 4.78% | 18.26% | 30.91% |
Gross Profit Gross Profit Growth | 4,068 | 3,764 | 3,623 | 3,399 | 3,119 | 2,653 |
Operating Income Operating Income Growth | 896.84 | -430.24 | 716.63 | 578.58 | -65.53 | 170.28 |
Net Income Net Income Growth | 940.76 | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 |
Earnings Per Share EPS Growth | 14.50 | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 |
EPS Growth | - | - | 41.80% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Neuroscience Total Neuroscience Growth | 3,049 | 2,878 | 2,698 | 2,708 | 2,761 | 2,335 |
Total Oncology Total Oncology Growth | 1,321 | 1,129 | 1,111 | 1,015 | 873.84 | 733.81 |
Other Product Other Product Growth | - | 14.17 | 11.47 | 13.85 | 6.64 | 9.8 |
High-Sodium Oxybate AG Royalty High-Sodium Oxybate AG Royalty Growth | 187.14 | 211.73 | 217.58 | 75.92 | - | - |
Other Royalty and Contract Other Royalty and Contract Growth | 35.83 | 34.01 | 30.21 | 21.34 | 17.95 | 15.24 |
Revenue (Total) Revenue (Total) Growth | 4,601 | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 2,200 | 2,442 | 2,993 | 1,626 | 881.48 | 591.45 |
Total Debt Total Debt Growth | 4,395 | 5,409 | 6,148 | 5,772 | 5,796 | 6,137 |
Net Cash (Debt) Net Cash Growth | -2,195 | -2,967 | -3,155 | -4,146 | -4,915 | -5,546 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -33.70 | -48.66 | -47.79 | -57.53 | -78.59 | -92.90 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,661 | 1,356 | 1,396 | 1,092 | 1,272 | 778.51 |
Capital Expenditures CapEx Growth | -69.75 | -58.75 | -38.07 | -23.96 | -29.05 | -27.64 |
Free Cash Flow Free Cash Flow Growth | 1,591 | 1,297 | 1,358 | 1,068 | 1,243 | 750.87 |
Free Cash Flow Growth | 25.79% | -4.48% | 27.13% | -14.07% | 65.53% | -15.12% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 88.42% | 88.21% | 89.05% | 88.64% | 85.23% | 85.76% |
Operating Margin | 19.49% | -10.08% | 17.61% | 15.09% | -1.79% | 5.50% |
Pretax Margin | 15.82% | -14.71% | 11.56% | 7.77% | -10.19% | -3.65% |
Profit Margin | 20.45% | -8.33% | 13.81% | 10.90% | -5.85% | -10.63% |
FCF Margin | 34.58% | 30.39% | 33.37% | 27.86% | 33.97% | 24.27% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.53 | - | 14.24 | 20.16 | - | - |
Forward PE | 10.14 | 7.67 | 5.72 | 6.29 | 8.54 | 8.23 |
P/FCF Ratio | 10.46 | 8.05 | 5.50 | 7.17 | 8.10 | 10.46 |
PS Ratio | 3.62 | 2.45 | 1.84 | 2.00 | 2.75 | 2.54 |